Procedimentos de levantamento do seio maxilar têm sido realizados para aumentar o volume ósseo e promover a estabilidade do implante, na região posterior de maxilas severamente atrofiadas. Ao longo dos anos, resultados de vários estudos demonstraram que alguns substitutos ósseos podem suportar implantes em função, após o levantamento de seio maxilar, igual ou melhor quando utilizado o osso autógeno. Neste estudo, foi avaliado o comportamento de um substituto ósseo completamente biodegradável (OsteoScaf™) no modelo experimental de levantamento de seio maxilar em coelhos. Além disso, ele foi comparado com o osso autógeno e outros dois substitutos ósseos, não totalmente biodegradáveis, disponíveis comercialmente (Bio-Oss® e BoneCeramic®). Avaliação clínica, tomografia computadorizada por feixe cônico, microtomografia computadorizada, análises microscópicas e análise molecular, através da técnica de PCR, foram realizadas após 2, 4 e 8 semanas de cirurgia. O levantamento de seio maxilar utilizando o osso autógeno demonstrou maior reabsorção, ao longo do tempo, comparado aos substitutos ósseos, os quais revelaram maior neoformação óssea após 8, 4 e 2 semanas, respectivamente. O grupo Bio-Oss® apresentou maior neoformação óssea, ao longo do tempo, quando comparado aos grupos Osteoscaf™ e BoneCeramic®, os quais foram qualitativamente emelhantes. O grupo BoneCeramic® mostrou uma resposta celular de células gigantes até 8 semanas. Concluiu-se que os substitutos ósseos, neste estudo, obtiveram melhor desempenho do que o osso autógeno, e o OsteoScaf™ demonstrou maior reabsorção do que os outros grupos, em todos períodos. / Maxillary sinus augmentation procedures have been applied to increase bone volume and to promote stability of implants in the severely atrophied posterior maxilla. Over the years, the outcomes of several studies have demonstrated that some bone substitutes can support implants in function after sinus augmentation as well as, or better than those with autogenous bone. Our experimental model evaluated the behavior of a fully biodegradable bone substitute (OsteoScaf™) in a rabbit sinus lift procedure. We compared this with autogenous bone and other two available non-biodegradable bone substitutes (Bio-Oss® and BoneCeramic®). Clinical evaluation, Cone Beam Computed Tomography, Microcomputed Tomography, microscopic and molecular evaluation were used for data analysis at 2, 4 and 8 weeks after sinus augmentation. Autogenous bone was more resorbed over time than the other materials. All bone substitutes showed more bone formation at 8, 4 and 2 weeks, respectively. Bio-Oss® showed more bone formation/timepoint than Osteoscaf™ and Boneceramic®, which were similar. Boneceramic® showed a florid giant cell response up to 8 weeks. We concluded that the bone graft materials all performed better than autogenous bone and OsteoScaf™ showed comparative bone growth yet greater degradation than the other two materials.

Endosseous implants have notably high success rates, yet a small percentage of implants still fail for unidentified reasons. Recent literature points to hyperglycemia, resulting from untreated or undiagnosed diabetes, as a possible contraindication in an otherwise apparently healthy population. To investigate the effect of surface design on peri-implant healing in the presence of hyperglycemia, STZ-treated rats were implanted with custom rectangular implants of two surface topographies: grit blasted (GB) and grit-blast with a calcium phosphate nanotopography (GB-DCD). Tensile testing was conducted at 5, 7, and 9 days post-operative. Results demonstrated hyperglycemia to delay early stages of the peri-implant healing. Contact osteogenesis was increased along the GB-DCD surface, even in an environment of uncontrolled hyperglycemia, and the GB-DCD surface outperformed the GB surface in both healthy and hyperglycemic animals, showing peri-implant bone matured more rapidly on nanotopographically complex surfaces, even in the presence of uncontrolled hyperglycemia.

No description available.

Recombinant human bone morphogenic proteins (rhBMPs) are extensively studied and employed clinically for treatment of various bone defects. Current clinical delivery vehicles suffer wasteful burst releases that mandate supra-physiological dosing driving concerns over safety and cost. It was therefore investigated whether a unique drug delivery vehicle sequestered within a composite scaffold could lower the burst release of rhBMP-2. PLGA-calcium phosphate tri-phasic composite scaffolds delivered model protein BSA with burst release of ~13% and sustained kinetics of 0.5-1.5% BSA/day up to 45 days. rhBMP-2 was delivered with zero burst release however at much lower levels, totaling 0.09% to 0.9 % release over 10 days, but had up to 6.3-fold greater bioactivity than fresh rhBMP-2 (p<0.05). In conclusion, the three-phase composite scaffold can deliver bioactive proteins with a reduced burst release and sustained secondary kinetics.

Recombinant human bone morphogenic proteins (rhBMPs) are extensively studied and employed clinically for treatment of various bone defects. Current clinical delivery vehicles suffer wasteful burst releases that mandate supra-physiological dosing driving concerns over safety and cost. It was therefore investigated whether a unique drug delivery vehicle sequestered within a composite scaffold could lower the burst release of rhBMP-2. PLGA-calcium phosphate tri-phasic composite scaffolds delivered model protein BSA with burst release of ~13% and sustained kinetics of 0.5-1.5% BSA/day up to 45 days. rhBMP-2 was delivered with zero burst release however at much lower levels, totaling 0.09% to 0.9 % release over 10 days, but had up to 6.3-fold greater bioactivity than fresh rhBMP-2 (p<0.05). In conclusion, the three-phase composite scaffold can deliver bioactive proteins with a reduced burst release and sustained secondary kinetics.